🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Carbetocin Monotherapy Versus Carbetocin Plus Oxytocin Infusion in Elective Cesarean Delivery: A Non-Inferiority Trial

RecruitingPhase 4Ages 18 Years - 45 YearsFemaleMansoura University
NCT07636421 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Background: Carbetocin is an established single-dose uterotonic agent for postpartum hemorrhage prophylaxis at elective cesarean delivery. Despite its proven efficacy, many clinicians routinely add a supplemental oxytocin infusion following carbetocin administration without evidence-based justification. Concurrent oxytocin receptor stimulation may be redundant, counterproductive through receptor desensitization, or incrementally beneficial - a mechanistic uncertainty that remains unresolved in the published literature. Objectives: To determine whether carbetocin monotherapy (100 micrograms IV bolus plus placebo infusion) is non-inferior to carbetocin plus supplemental oxytocin infusion (10 IU over 4 hours) in preventing the need for additional uterotonic agents within 24 hours of elective cesarean delivery. Study Design: Prospective, randomized, double-blind, placebo-controlled, non-in

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adult women aged 18 to 45 years * Scheduled for elective non-emergency cesarean delivery * Spinal anesthesia planned and administered as the sole anesthetic technique * Singleton pregnancy at gestational age of 37 completed weeks or more * ASA physical status II * Preoperative hemoglobin of 9 g/dL or more * Able to provide written informed consent in Arabic or English Exclusion Criteria: * Emergency or crash cesarean delivery * Placenta previa, placenta accreta spectrum disorder, or other abnormal placentation * Known uterine anomalies likely to impair contractility including fibroids greater than 5 cm, bicornuate or unicornuate uterus * Grand multiparity defined as 5 or more previous deliveries * Multiple gestation including twins or higher order * Polyhydramnios defined as amniotic fluid index greater than 24 cm * Prior oxytocin augmentation in current pregnancy for more than 6 hours * Known hypersensitivity to carbetocin, oxytocin, or any formulation excipient * Severe preeclampsia, eclampsia, or HELLP syndrome * Cardiovascular disease including arrhythmia, valvular disease, cardiomyopathy, or ischemic heart disease * Known coagulopathy or thrombocytopenia with platelets less than 100 x 10\^9/L * Hepatic or renal impairment * Body mass index greater than 40 kg/m2 at time of delivery * Enrollment in another interventional clinical trial
💊

What it tests

  • Carbetocin
  • Oxytocin
  • Placebo Saline Infusion
📍

Where

1 site
Qassim University Medical City
Buraidah, Saudi Arabia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy